AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Neill, A.
Right arrow Articles by Chopra, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Neill, A.
Right arrow Articles by Chopra, I.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2000, p. 3163-3166, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

RNA Polymerase Inhibitors with Activity against Rifampin-Resistant Mutants of Staphylococcus aureus

Alexander O'Neill,1 Brunello Oliva,2 Christopher Storey,1 Anthony Hoyle,1 Colin Fishwick,3 and Ian Chopra1,*

Antimicrobial Research Centre and Division of Microbiology1 and Antimicrobial Research Centre and School of Chemistry,3 University of Leeds, Leeds LS2 9JT, United Kingdom, and Department of Experimental Medicine, University of L'Aquila, Coppito-67100, L'Aquila, Italy2

Received 20 March 2000/Returned for modification 21 June 2000/Accepted 2 August 2000

A collection of rifampin-resistant mutants of Staphylococcus aureus with characterized RNA polymerase beta -subunit (rpoB) gene mutations was cross-screened against a number of other RNA polymerase inhibitors to correlate susceptibility with specific rpoB genotypes. The rpoB mutants were cross-resistant to streptolydigin and sorangicin A. In contrast, thiolutin, holomycin, corallopyronin A, and ripostatin A retained activity against the rpoB mutants. The second group of inhibitors may be of interest as drug development candidates.

* Corresponding author. Mailing address: Antimicrobial Research Centre and Division of Microbiology, University of Leeds, Leeds LS2 9JT, United Kingdom. Phone: 44 113 233 5604. Fax: 44 113 233 5638. E-mail: i.chopra{at}leeds.ac.uk.

Antimicrobial Agents and Chemotherapy, November 2000, p. 3163-3166, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.